TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021
TRACON Pharmaceuticals (NASDAQ:TCON) will report its Q1 2021 financial and operational results on May 5, 2021, after market close. A conference call is scheduled for the same day at 4:30 PM ET to discuss the results and provide updates on corporate activities. The company develops targeted cancer therapies and is focused on securing partnerships to lead U.S. regulatory, clinical development, and commercialization for its innovative product pipeline. Key assets include Envafolimab and TRC253.
- Pre-announcement suggests ongoing development and potential upcoming positive results.
- Strategic focus on partnerships enhances potential for cost-effective product commercialization.
- Diverse product pipeline includes late-stage candidates like Envafolimab and TRC253.
- Lack of specific financial metrics may create uncertainty for investors.
- The announcement does not indicate any recent positive developments or milestones.
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its first quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, May 5, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
| Conference call and webcast: | |
| Date: | May 5, 2021 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 8852857 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | 212-915-2578 |
| mwiggins@traconpharma.com |
FAQ
When will TRACON Pharmaceuticals report its Q1 2021 financial results?
What time is the TRACON Pharmaceuticals conference call?
What is the focus of TRACON Pharmaceuticals?
What are the main products in TRACON Pharmaceuticals' pipeline?
